Array BioPharma (ARRY) PT Raised to $20 at Stifel
Tweet Send to a Friend
Stifel raised its price target on Array BioPharma (NASDAQ: ARRY) to $20.00 (from $15.00) while maintaining a Buy rating.Analyst Stephen ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
